2213-63-0Relevant articles and documents
-
Kuhn et al.
, p. 1843 (1968)
-
Functionalization of gold nanoparticles with two aminoalcohol-based quinoxaline derivatives for targeting phosphoinositide 3-kinases (PI3Kα)
Araújo, Janine,Menezes, Fabrício G.,Silva, Heloiza F. O.,Vieira, Davi S.,Silva, Sergio R. B.,Bortoluzzi, Adailton J.,Sant'Anna, Celso,Eugenio, Mateus,Neri, Jannyely M.,Gasparotto, Luiz H. S.
, p. 1803 - 1811 (2019)
Quinoxaline derivatives have attracted considerable attention due to their vast range of applications that includes electroluminescence and biomedicine. Concerning the latter, the literature has shown that compounds with a quinoxaline motif bind quite efficiently to phosphatidylinositol-4,5-bisphosphate 3-kinases (PI3Ks), which are enzymes found to be overexpressed in some types of neoplasms. In the present study, gold nanoparticles (AuNPs) were easily functionalized with 2,3-diethanolminoquinoxaline (DEQX) and 2-(2,3-dihydro-[1,4]oxazino[2,3-b]quinoxalin-4-yl)ethanol (OAQX). We made use of glycerol in alkaline media as reducing agent and the quinoxalines served as capping ligands to stabilize the AuNPs. This is the first report on the modification of a nanostructure with quinoxalines. Functionalization confers nanoparticles the required specificity to target only cancer cells, which opens possibilities for phototherapy since the modified AuNPs would concentrate in the tumor tissue as a consequence of PI3Kα overexpression. Molecular dynamics simulations have shown that DEQX and OAQX are potential inhibitors of PI3Kα since they bind to the active site of the enzyme in a way similar to other known inhibitors.
One-pot synthesis of novel substituted quinoxaline piperazine derivatives and their antimicrobial activities
Abdel-Hafez, Shams H.,Fahmy, Heba Mohamed,Hessien, Mahmoud M.,Narasimha Reddy, Y.,Reddy G, Nagaraja,Reddy Mardi, Radhakrishna,Reddy T, Sreenivasulu,Seku, Kondaiah,Shalan, Ahmed Esmail
, (2022/01/06)
The present investigation reports the preparation of 1-(4-(tolyl quinoxaline-2-yl) piperazine-1-yl) derivatives catalyzed via polymer supported reagents. We have developed novel quinoxaline piperazine derivatives from 2,3-dichloroquinoxaline, wherein one chloro group is substituted with an aryl group, and the other is substituted by alkyl and aryl piperazine derivatives, through aromatic nucleophilic substitution reaction, and Suzuki coupling reactions to substituted quinoxaline-piperazine derivatives (5a-5g) compounds. The synthesized compounds were identified using FTIR, 1H NMR, 13C NMR and LC-MS. The synthesized compounds were examined for their antimicrobial activity. The results indicated that 5d, 5f and 5 g compounds have exhibited well to moderate antibacterial activity with the zone of inhibition of 18, 22 and 21 mm for Escherichia coli (40 μg/mL), and 17, 19 and 17 mm for Staphylococcus aureus (40 μg/mL). Besides, 5f compound showed respectable results to moderate antifungal activity with the zone of inhibition of 21 mm for Aspergillus niger (40 μg/mL) and 19 mm for Candida albicans (40 μg/mL). The established synthetic route is beneficial to develop various key intermediates as well as active pharmaceutical ingredients for pharmaceutical applications.
Novel molecular targeting anti-tumor aza-steroid derivative based on lipid toxicity and preparation and application thereof
-
Paragraph 0178; 0180; 0192; 0205; 0224, (2021/08/19)
The invention provides a novel molecular targeting anti-tumor aza-steroid derivative based on lipid toxicity and a preparation method and application thereof, and belongs to the field of chemical medicines. The derivative is a compound as shown in a formula I, or a salt thereof, or a stereoisomer thereof. The compound is low in toxicity or basically non-toxic to normal cells, has an obvious inhibition effect to tumor cell lines, particularly has good lipid toxicity selectivity to tumor cells such as liver cancer, lung cancer and the like in vivo, and has an obvious inhibition effect; meanwhile, the compound can effectively activate SREBP1 and PPAR gamma, inhibit lipid transport MTTP, cause lipid aggregation in tumor cells and cause lipid toxicity of the tumor cells. The compound can be used for treating liver cancer, lung cancer and the like in a molecular targeting manner, is low in toxicity or even non-toxic, and has a good application prospect.
Anti-MRSA drug discovery by ligand-based virtual screening and biological evaluation
Lian, Xu,Xia, Zhonghua,Li, Xueyao,Karpov, Pavel,Jin, Hongwei,Tetko, Igor V.,Xia, Jie,Wu, Song
, (2021/06/15)
S. aureus resistant to methicillin (MRSA) is one of the most-concerned multidrug resistant bacteria, due to its role in life-threatening infections. There is an urgent need to develop new antibiotics against MRSA. In this study, we firstly compiled a data set of 2,3-diaminoquinoxalines by chemical synthesis and antibacterial screening against S. aureus, and then performed cheminformatics modeling and virtual screening. The compound with the Specs ID of AG-205/33156020 was discovered as a new antibacterial agent, and was further identified as a Gyrase B (GyrB) inhibitor. In light of the common features, we hypothesized that the 6c as the representative of 2,3-diaminoquinoxalines also inhibited GyrB and eventually proved it. Via molecular docking and molecular dynamics simulations, we identified binding modes of AG-205/33156020 and 6c to the ATPase domain of GyrB. Importantly, these GyrB inhibitors inhibited the MRSA strains and showed selectivity to HepG2 and HUVEC. Taken together, this research work provides an effective ligand-based computational workflow for scaffold hopping in anti-MRSA drug discovery, and discovers two new GyrB inhibitors that are worthy of further development.
